MENU
+Compare
NAMS
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$18.20
Change
-$0.18 (-0.98%)
Capitalization
2B

NAMS NewAmsterdam Pharma Company NV Forecast, Technical & Fundamental Analysis

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated... Show more

NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NAMS with price predictions
Apr 01, 2025

NAMS's RSI Indicator stays in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for NAMS crossed bullishly above the 50-day moving average on March 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in of 163 cases, the price rose further within the following month. The odds of a continued upward trend are .

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 106 cases where NAMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NAMS turned negative on March 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

NAMS moved below its 50-day moving average on March 31, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NAMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.640) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (37.736) is also within normal values, averaging (251.391).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NAMS is expected to report earnings to fall 46.59% to -49 cents per share on May 07

NewAmsterdam Pharma Company NV NAMS Stock Earnings Reports
Q1'25
Est.
$-0.50
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.32
Q2'24
Beat
by $0.17
Q1'24
Missed
by $0.44
The last earnings report on February 26 showed earnings per share of -93 cents, beating the estimate of -95 cents. With 1.43M shares outstanding, the current market capitalization sits at 2.00B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Gooimeer 2-35
Phone
+31 352062971
Employees
29
Web
https://www.newamsterdampharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALPAX10.56N/A
N/A
American Century Focused Lg Cap Val A
OIEFX23.81N/A
N/A
JPMorgan Equity Income R2
IYSMX15.55N/A
N/A
Macquarie Smid Cap Core Fund Class R
LFGOX32.13N/A
N/A
Lord Abbett Focused Growth F3
AGYCX15.30N/A
N/A
American Century Global Gold C

NAMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-10.21%
QURE - NAMS
51%
Loosely correlated
-6.51%
CMRX - NAMS
50%
Loosely correlated
-0.12%
CRDF - NAMS
34%
Loosely correlated
-2.55%
GYRE - NAMS
32%
Poorly correlated
-16.97%
CGON - NAMS
29%
Poorly correlated
-9.96%
More